Transcatheter aortic valve implantation for stenosed and regurgitant aortic valve bioprostheses CoreValve for failed bioprosthetic aortic valve replacements.
Transcatheter aortic valve implantation is increasingly being used to treat severe aortic stenosis in patients with high operative risk. In an aging population the incidence of aortic stenosis is rising, and increasing numbers of elderly patients are undergoing aortic valve replacement with bioprosthetic valves. Therefore, there is a corresponding increase in prosthetic degeneration. This presents cardiologists with a cohort of patients for whom the risk of re-do aortic valve surgery is prohibitive. We present the first series of such patients with degenerative bioprosthetic stenosis or regurgitation successfully treated with CoreValve (Medtronic, Luxembourg) implantation.
Khawaja
Muhammed Z
MZ
Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. drzeeshan@doctors.org.uk
Haworth
Peter
P
Ghuran
Azad
A
Lee
Lorraine
L
de Belder
Adam
A
Hutchinson
Neville
N
Trivedi
Uday
U
Laborde
Jean-Claude
JC
Hildick-Smith
David
D
D000368:Aged; D000369:Aged, 80 and over; D001022:Aortic Valve Insufficiency / Q000175:diagnosis / Q000209:etiology / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000175:diagnosis / Q000209:etiology / Q000601:surgery*; D001705:Bioprosthesis / Q000009:adverse effects*; D006328:Cardiac Catheterization; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D011475:Prosthesis Failure; D012086:Reoperation